Methods of enhancing anti-tumour immunity in a mammal

Details Methods of enhancing anti-tumour immunity in a mammal Methods of enhancing anti-tumour immunity in a mammal

A - Human Necessities

61

K

A61K 48/00 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) A61P 37/04 (2006.01) C07K 14/54 (2006.01) C07K 14/705 (2006.01) C12N 5/10 (2006.01) C12N 15/85 (2006.01)

Patent

CA 2253790

Anti-tumour immune responses are elicited by engineering genetically lymphoma tumour cells to express interleukin- 12 (IL- 12), the combination of B7-1 and interleukin- 12, or by increasing endogenous expression of the costimulatory molecule B7-2. The combination of B7-1 and IL-12 is most effective in minimal disease settings when the tumour cell engineered genetically to express both molecules is inoculated into the same site of tumour burden. In addition, increasing the expression of endogenous B7-2 provides another method by which anti-tumour immunity is generated against unmodified tumour cells. The mechanisms of the anti-tumour immune response are multifactorial involving T cells as well as natural killer (NK) cells.

Affiliated with

Also associated with

Rating

Methods of enhancing anti-tumour immunity in a mammal does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of enhancing anti-tumour immunity in a mammal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing anti-tumour immunity in a mammal will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1425812